SFN-treated TNBCs (MDA-MB-231-Luc-D3H1 and JygMC(A)GFP/Luc) showed proliferation inhibition, suppression of self-renewal of breast CSCs, and a reduced number and diameter of primary and tertiary tumor spheres, while SFN-treated CD49f+/CD24−/CD44+ breast CSCs showed a significant reduction in the number of secondary tumor spheres as well [161]. This evidence concerns the gene CD44 and neoplasm.